论文部分内容阅读
作者单用4去甲基-表鬼臼毒-β-D-硫茂亚甲基葡萄糖苷(Etoposide,VP-16-213)治疗3例初治失败和难治性急单患儿。例1是2月男婴,为M_(5b);例2是1(7/(12))男孩,M_(5a);例3是14岁女孩,M_(5a)。例1、2用柔红霉素与Ara-C联合初治失败,例3是经联合化疗缓解后第三次复发。各例均单用VP-16-213,剂量为100-200mg/m~2/日,静脉注射,连用5天。诱导期间加强支持治疗,输新鲜全血、血小板等。维持剂量自每周1次,200mg/m~2,至每2周400mg/m~2。例1、例2鞘内注射Ara-C,MTX和氢化可的松赖以预防CNS白血病。3例均获CR,分别维持11、6和7个月。毒性反应包括骨髓抑制、脱发、恶心、呕吐和肾功能损害,均可耐受。毒性反应与剂量有关。可见,VP-16-213
The authors treated only 4 demethyl-epodopsin-β-D-thiomethylene glucoside (VP-16-213) in 3 patients with untreated and refractory acute single children. Example 1 is a February baby boy, M_(5b); Example 2 is a 1(7/(12)) boy, M_(5a); Example 3 is a 14-year-old girl, M_(5a). Cases 1 and 2 failed to be treated with daunorubicin combined with Ara-C. Case 3 was the third relapse after remission with combination chemotherapy. In each case, VP-16-213 was used alone, and the dose was 100-200 mg/m 2 /day for intravenous injection for 5 days. During the induction period, supportive treatment is strengthened and fresh whole blood, platelets, etc. are lost. The maintenance dose was from 200 mg/m 2 once a week to 400 mg/m 2 every 2 weeks. Examples 1 and 2 were intrathecalally injected with Ara-C, MTX, and hydrocortisone to prevent CNS leukemia. CR was obtained in all 3 patients and maintained for 11, 6 and 7 months respectively. Toxic reactions include myelosuppression, alopecia, nausea, vomiting, and impaired renal function, which can be tolerated. The toxicity is related to the dose. Visible, VP-16-213